Lead partner
Type of activity

Core research objectives

  1. To expand knowledge and understanding of the advantages and disadvantages of the different approaches to assess clinical cost-effectiveness
  2. To consolidate the lessons from existing research, and to identify what new research would be of greatest value to improve HTA decision-making processes
  3. To advance the methodology in HTA by systematically exploring alternative means of assessing value for money and tracing the implications for the conduct of HTA and the use of cost-effectiveness data to inform decisionmaking regarding which health technologies to adopt

During the first two years of the project, WP1 has completed the following tasks:

  • Creation of a classification for the main factors determining the HTA systems in the EU ranging from system-wide to product-specific variables.
  • Construction of a database on cancer drug HTA for 8 EU countries.
  • Empirical analysis of the main factors driving HTA decisions on cancer drugs for 8 countries.

During third and final year of the project, WP1 has completed the following tasks:

  • Extended the dataset to 10 countries, followed by econometric analysis and interpretation of results.
  • Extended the database to other therapeutic areas, in particular, Multiple Sclerosis and Rheumatoid Arthritis.
  • Developed case studies to increase the value of the research, by deepening the empirical analysis of the full set of drugs and countries.

Summary of conclusions
Why Do Some Countries Approve a Cancer Drug and Others Don't?

Principal Investigator: Professor John Cairns

Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.